BOSTON - On Feb. 12, the federal judge in Massachusetts overseeing the multidistrict litigation involving purchasers of Nexium's antitrust claims - that the manufacturer of the heartburn medication and generic drug manufacturers entered into reverse-payment agreements to keep generic versions of the medication out of the market - made rulings on pending summary judgment motions and continued the date the trial was to commence (In re Nexium [Esomeprazole] Antitrust Litigation, No. 12-md-02409, D. Mass.; 2014 U.S. Dist. LEXIS 17718).